Christine Cotton Preservation archive
English Français

← All interviews · All research follow-ups →

"La Commission veut prolonger ce pass sans base scientifique !" Virginie Joron, Christine Cotton

Ligne Droite • La matinale de Radio Courtoisie · YouTube · Watch ▶

📅 2022-06-14🎙️ Radio Courtoisie host with Virginie Joron (MEP, Identité et Démocratie)📺 Radio Courtoisie — La matinale (Ligne droite)⏱ 30 min
“If Pfizer had wanted to know who'd had COVID in its trial, they would have done anti-nucleocapsid serology. With that table, you get 56 vaccine cases, not 8 — efficacy is around 56%, not 95%.”

Key statements

  • Joron warns the Commission wants to extend the EU digital COVID certificate to June 2023 with no efficacy study, while the vaccines themselves remain in trial through 2023. ▶ 05:01
    Sources: EU Regulation 2021/953 on the EU Digital COVID Certificate (proposed extension, June 2022)
  • Background: a US federal judge (Mark Pittman) ordered Pfizer to release 55,000 pages of clinical trial documents per month, after the FDA had requested 75 years. The full dataset was scheduled for completion by end-2022. ▶ 09:30
    Sources: PHMPT v. FDA court order (Pittman, Jan 2022)
  • Cotton examined the released SAS data tables — the working files of any biostatistician — rather than the administrative paperwork or filled-in patient case-report forms. ▶ 10:12
    Sources: Pfizer C4591001 SAS datasets (court-released)
  • Had Pfizer wanted to know who'd had COVID in the trial, they would have used anti-nucleocapsid serology. That table exists in the released documents. ▶ 11:38
    Sources: Pfizer C4591001 anti-nucleocapsid serology dataset (court-released)
  • Recomputed on the anti-N serology dataset, the vaccine arm has 56 COVID cases (vs. 162 placebo) — not the 8 vs. 162 used for the headline. Efficacy is closer to 56%, not 95%, and this number was never disclosed by Pfizer in December 2020. ▶ 12:45
    Sources: Pfizer C4591001 SAS datasets (court-released)
  • The trial never studied transmission. In January 2021, when the public was told two doses would restore normal life, Pfizer had no transmission data; later real-world studies were retrofitted to claim a transmission effect. ▶ 14:03
    Sources: Pfizer C4591001 Protocol
  • Five sites recruited nearly 10,000 of the trial's ~38,000 participants — a major imbalance that should have triggered a per-site analysis (it isn't in the reports). One Argentine military hospital alone recruited over 5,000 patients, ramping from 60 to 240 per day. ▶ 19:23
    Sources: Pfizer C4591001 SAS datasets (court-released)
  • Patient IDs in the SAS tables violate the CDISC standard: at the Argentine site (1231), a block of participants is numbered "4444" — an undocumented numbering inconsistent with industry norms. ▶ 20:23
    Sources: Pfizer C4591001 SAS datasets (court-released); CDISC standards
  • Protocol deviations show that vaccine-arm participants who reported COVID-like symptoms were less likely to receive a follow-up PCR visit than placebo-arm participants — confirming the case-detection bias in favor of the vaccine. ▶ 20:42
    Sources: Pfizer C4591001 SAS datasets (court-released)
  • Joron's broader critique: Pfizer effectively decides the validity of its own vaccine; over a million adverse events sit in the EMA database with no formal investigation; the pass sanitaire is a tool to coerce vaccination, not curb transmission. ▶ 22:49
    Sources: EudraVigilance database
  • Joron flags that the Commission has suspended its planned purchase of Valneva (a more conventional protein-based vaccine for the vaccine-hesitant) while sitting on 4 billion mRNA doses with short shelf-lives. ▶ 24:27
    Sources: EU Advance Purchase Agreements (Valneva and Pfizer/BioNTech)
  • The first Pfizer report showed no statistically demonstrated effect on severe forms (too few cases), zero severe cases in adolescents, zero in children. The "prevents severe forms" narrative rests entirely on later real-world studies — most of them methodologically flawed (Cotton flags EPI-PHARE specifically). ▶ 26:53
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020); EPI-PHARE / ANSM real-world studies
  • OPECST (the French parliamentary office for science and technology assessment) published an interim report acknowledging a lack of transparency on adverse events. Cotton testified — but her hearing was not made public. ▶ 28:05
    Sources: OPECST interim report on COVID-19 vaccine adverse events

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 SAS datasets (court-released) — PHMPT v. FDA court order (Pittman, Jan 2022)
  • EU Regulation 2021/953 (EU Digital COVID Certificate) — EUR-Lex
  • EudraVigilance adverse-event database — EMA
  • EU Advance Purchase Agreements (Pfizer/BioNTech, Valneva) — European Commission transparency portal
  • OPECST interim report on COVID-19 vaccine adverse events — Sénat — Office parlementaire d'évaluation des choix scientifiques et technologiques
  • EPI-PHARE / ANSM real-world COVID vaccine studies — epi-phare.fr

Research follow-ups

All research follow-ups →